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Abstract 23 
The opposing activities of 53BP1 and BRCA1 influence pathway choice of DNA double-strand 24 
break repair. How BRCA1 counters the inhibitory effect of 53BP1 on DNA resection and 25 
homologous recombination is unknown. Here we identify the site of BRCA1-BARD1 required 26 
for priming ubiquitin transfer from E2~ubiquitin. We demonstrate that BRCA1-BARD1’s 27 
ubiquitin ligase activity is required for repositioning 53BP1 on damaged chromatin. We confirm 28 
H2A ubiquitylation by BRCA1-BARD1 and show that an H2A-ubiquitin fusion protein promotes 29 
DNA resection and repair in BARD1 deficient cells. We show BRCA1-BARD1 function in 30 
homologous recombination requires the chromatin remodeler SMARCAD1. SMARCAD1 binding 31 
to H2A-ubiquitin, optimal localization to sites of damage and activity in DNA repair requires its 32 
ubiquitin-binding CUE domains. SMARCAD1 is required for 53BP1 repositioning and the need 33 
for SMARCAD1 in Olaparib or camptothecin resistance is alleviated by 53BP1 loss. Thus BRCA1-34 
BARD1 ligase activity and subsequent SMARCAD1-dependent chromatin remodeling are critical 35 
regulators of DNA repair. 36 
 37 
  38 
 39 
 40 
 41 
Introduction. 42 
 43 
Inheritance of a mutation in the breast cancer susceptibility gene 1 (BRCA1) confers a high 44 
risk of breast and ovarian cancer, and tumours in BRCA1 gene mutation carriers are 45 
characterized by excessive genome instability. The BRCA1 protein is implicated in several 46 
aspects of genome stability: including check-point promotion, DNA cross-link repair, 47 
replication fork stability and DNA double-strand break (DSB) repair1-3. In DSB repair it is most 48 
prominently associated with homologous recombination (HR) where it promotes the 49 
essential step of DNA resection by opposing the block on resection contributed by the p53 50 
binding protein 53BP1 and its effector proteins (reviewed in 3,4). In the absence of BRCA1, 51 
DSBs are repaired by toxic non-homologous end joining (NHEJ)5. BRCA1 associates with the 52 
resection protein CtIP to relieve the 53BP1 block6, but how BRCA1 contributes is not known. 53 
 54 
 55 
In familial breast and ovarian cancer patients, pathogenic and unclassified substitution 56 
variants in the BRCA1 gene are found across the region encoding the first hundred amino 57 
acids. This part of BRCA1 contacts its heterodimeric binding partner, the BRCA1-associated 58 
RING domain protein ,BARD1, and E2 Ubiquitin (Ub) conjugating enzymes, allowing BRCA1-59 
BARD1 to function as an E3 Ub ligase in the transfer of Ub from E2 conjugating enzymes to 60 
target proteins7. Several targets have been proposed and recently BRCA1-mediated 61 
ubiquitination of histone 2A (H2A) has been mapped8. However a role, if any, played by 62 
the BRCA1 E3 Ub ligase activity in DNA repair has been controversial9-11. Evidence from 63 
Brca1 deficient mice has suggested H2A ubiquitination regulates global heterochromatin 64 
integrity, and through transcriptional repression of satellite RNA is responsible for multiple 65 
disparate cellular functions of Brca1, including the promotion of genomic integrity9. How 66 
increased satellite RNA impacts HR repair is not clear and the phenomenon of increased 67 
satellite RNA expression has not been universally observed in Brca1 deficient models 12. 68 
Indeed other models of Brca1 dysfunction have suggested a restricted role, or no role, for 69 
its biochemical function in DNA repair10,11. 70 
Here we set out to investigate the role of the BRCA1-BARD1 Ub ligase activity in the DNA 71 
damage response in human cells. Our data suggest a model in which chromatin modification by 72 
BRCA1-BARD1 E3 Ub ligase activity repositions 53BP1 and drives completion of resection 73 
through promoting the activity of the SWI/SNF-Related, Matrix-Associated Actin-Dependent 74 
Regulator of Chromatin, SMARCAD1. 75 
 76 
 77 
Results 78 
A charged residue required in Type 1 RING:RING E3s. 79 
Ub priming structures that promote the transfer of the donor Ub from a Ub-loaded E2 80 
conjugating enzyme have been identified in RING finger protein 4, RNF4, and Casitas B-81 
lineage Lymphoma, C-CBL, E3 Ub ligases13,14. However no surfaces analogous to these have 82 
yet been found in E3 Ub ligases characterized by helical interactions between protomers, 83 
known as Type I 15. These include the human homologue of yeast radiation mutant 18 84 
(RAD18), the polycomb repressor complex ligase RING1A or RING1B complexes and BRCA1-85 
BARD1. Nevertheless minimal BRCA1-BARD1 N-terminal fragments exhibit base-level Ub ligase 86 
activity16,17 indicating that the elements necessary for Ub transfer are present within the 87 
polypeptides.  88 
  89 
To identify a possible Ub-binding interface we overlaid the RNF4-RNF4-Ub~E2 structure (PDB: 90 
4AP413) onto N-terminal BRCA1-BARD1 (PDB: 1JM718). In the superposition BARD1 residues 91 
91-99 are in a similar location to the RNF4 residue, Y193, which engages Ub13. A mutational 92 
scan across the BARD1 region revealed that a heterodimer bearing a substitution at R99 93 
exhibited reduced activity (Supplemental Fig. 1A&B). Substitution of R99 to a lysine was 94 
tolerated but the activity of the heterodimer with glutamic acid (R99E) was severely impaired 95 
with all Ub conjugating enzymes of the Ub-Conjugating Enzyme 2D (UBE2D) family (Fig 1A, 96 
Supplemental Fig. 1C-E). Substitutions at R99 did not affect BARD1 interaction with BRCA1 97 
(Fig 1B) but the R99E mutant heterodimer showed a weaker interaction with conjugation-98 
proficient E2 (Supplemental Fig. 1F).  99 
 100 
In the superimposition R99-BARD1 is predicted to be close to the D32 side chain of Ub 101 
(Supplemental Fig. 1G). To test whether R99-BARD1 contacts Ub, we made a D32R mutation 102 
in Ub. This mutant was processed slightly less well than Wild Type (WT) Ub by the BRCA1-103 
BARD1 heterodimer, but the weak catalytic activity of the R99E-BARD1 mutant heterodimer 104 
was substantially improved with D32R-Ub (Fig 1C), suggesting contact with Ub contributes to 105 
activity. Transfer reactions of Ub from UBE2D1 or UBE2D3 E2 enzymes to free lysine revealed 106 
reduced discharge rates with the R99E heterodimer compared to WT proteins (Fig 1D, 107 
Supplemental Fig 1H). Thus R99-BARD1 promotes heterodimer interaction with the Ub~E2 108 
thioester conjugate through Ub and is required to promote the discharge of Ub from the E2 109 
contacting BRCA1. 110 
 111 
 112 
We noted that other Type 1 RING E3 ligases carry positively charged residues (R or K) at 113 
positions analogous to R99-BARD1 (Fig 2A & Supplemental Fig 2A). For example in the 114 
heterodimeric protein formed of B cell-specific Moloney murine leukemia virus integration 115 
site 1, BMI1  (also known as polycomb group RING finger protein 4 (PCGF4)) with RING1B,  116 
BMI1-RING1B, the ‘inactive’ partner, BMI1, has an equivalent lysine, K73, while the 117 
protomer contacting the E2, RING1B, lacks a similarly located charged residue (as does 118 
BRCA1). We mutated K73E in BMI1 and R76A in RAD18. While WT RAD18 induced PCNA 119 
mono-ubiquitination on ectopic expression and also potentiated PCNA mono-120 
ubiquitination following UV exposure, the R76A mutant failed to do so (Fig. 2B). Similarly 121 
the K73E-BMI1-RING1B heterodimer lacked the ability to catalyze mono-ubiquitination of 122 
H2A in nucleosomes in vitro (Fig. 2C, see Supplemental Fig. 2B for co-purification). In cells 123 
ectopic expression of K73E-BMI1 but not WT protein inhibited DSB Ub signaling and WT-124 
BMI1 but not K73E-BMI1 was able to rescue repair of a gene conversion substrate in cells 125 
depleted of endogenous BMI1 (Supplemental Fig. 2C-E). These data are consistent with 126 
the effect of inhibiting RING1A and RING1B19. We suggest that a charged interface 127 
between Type I dimeric RING E3 ligases and the donor Ub activates the E2~Ub thioester. In 128 
the two heterodimeric complexes this key interface is provided by protomers previously 129 
described as simply scaffold proteins, BARD1 and BMI1. 130 
 131 
 132 
Ligase activity is required for a subset of BRCA1 responses. 133 
To address possible roles of the BRCA1-BARD1 Ub ligase activity we depleted HeLa cells of 134 
endogenous BARD1 and expressed siRNA resistant full length WT BARD1 cDNA or mutant 135 
forms bearing BARD1 amino acid substitutions R99E or L44R (illustrated in Fig. 3A). L44R 136 
 introduces a large hydrophilic residue in the hydrophobic helical face of BARD1 preventing 137 
interaction with BRCA1 20. Complementation of cells with L44R-BARD1 failed to support 138 
heterodimer formation, heterodimer stability, or promote endogenous BRCA1 localization to 139 
irradiation-induced foci (IRIF) (Supplemental Fig. 3A-C). In contrast R99E-BARD1 retained 140 
dimerization with BRCA1, promoted both BRCA1 stability and localization to IRIF (Supplemental 141 
Fig. 3A-C). Neither R99E-BARD1, nor L44R-BARD1 purified complexes exhibited Ub ligase 142 
activity (Supplemental Fig. 3D). Thus L44R-BARD1 is both heterodimer and ligase disruptive in 143 
cells, whereas the R99E-BARD1 variant is ligase defective but promotes heterodimer formation. 144 
 145 
To differentiate potential roles for ligase activity from those of the heterodimer in DNA 146 
repair we compared survival of cells depleted for endogenous BARD1 and complemented 147 
with the separation of function variants in response to various DNA damaging agents. BARD1 148 
depletion or complementation with L44R-BARD1 resulted in sensitivity to each DNA 149 
damaging agent tested and complementation with the WT-BARD1 protein restored 150 
resistance (Fig. 3B). Strikingly R99E-BARD1 complemented cells exhibited resistance to some 151 
agents but not to others. They were resistant to replication fork stalling and slowing agents, 152 
hydroxyurea (HU) and aphidicolin, and to the intra-strand-cross-linking (ICL) agent, cisplatin, 153 
but sensitive to camptothecin (topoisomerase-I poison), etoposide (topoisomerase-II 154 
poison), Olaparib (AZD-2281, PARP inhibitor) and irradiation (Fig. 3B). These data prompted 155 
us to revisit the I26A substitution of BRCA1 that disrupts interaction with E2 conjugating 156 
enzymes (7and also shown in Supplemental Fig. 3E). Cells depleted for endogenous BRCA1 157 
and complemented with I26A-BRCA1 were also sensitive to Olaparib (Fig. 3C), supporting the 158 
notion that the BRCA1-BARD1 Ub ligase activity supports Olaparib resistance. 159 
 160 
 161 
Ligase activity promotes 53BP1 repositioning and resection.  162 
The sensitivities of ligase defective cells suggest a role in the promotion of HR, a process 163 
begun by resection of DNA ends. To interrogate the HR pathway, we first examined the 164 
ssDNA binding protein Replication protein A (RPA), which forms foci after irradiation and is 165 
indicative of resection. Cells complemented with R99E-BARD1 or L44R-BARD1 exhibited 166 
reduced numbers, size and intensity of RPA foci and also had reduced foci of the human 167 
homologue of yeast radiation mutant 51, RAD51, compared to WT-BARD1 complemented 168 
cells (Fig 4A, Supplemental Figure 4A). These data suggest ligase activity relates to the role of 169 
BRCA1 in promoting DNA resection prior to formation of the RAD51 nucleofilament in HR.  170 
 171 
53BP1 and its effector proteins act to block DNA resection in the absence of BRCA14.  As 172 
anticipated, depletion of 53BP1 alleviated the requirement for BRCA1-BARD1 Ub ligase 173 
activity in Olaparib and Camptothecin resistance, increased RAD51 and RPA foci after IR and 174 
improved repair of an integrated HR substrate in a manner that was dependent on the ‘CtBP-175 
Interacting Protein’ and nuclease, CtIP (Fig 4B, Supplemental Fig. 4B-F). Depletion of the 176 
53BP1 effector proteins, human REV7 (also known as MAD2 mitotic arrest deficient-like 2, 177 
MAD2L2)21,22or Artemis 23, similarly improved survival of R99E-BARD1 complemented cells 178 
after IR, Olaparib or camptothecin to differing degrees depending on the agent (Supplemental 179 
Fig. 5A-C).  180 
 181 
These data reveal for the first time that the Ub ligase activity of BRCA1-BARD1 contributes to 182 
the function of BRCA1 in DNA resection, and consistent with the described relationship 183 
between BRCA1 and 53BP1 it can be by-passed by loss of 53BP1 or its effector proteins. In 184 
 contrast, the resistance of BRCA1 depleted cells to HU was not restored by 53BP1 depletion 185 
(Fig. 4C) consistent with the notion that the Ub ligase-independent function(s) of BRCA1 do 186 
not interact with 53BP1. 187 
The recruitment of BRCA1 into the core of IRIF is associated with eviction of 53BP1 to the 188 
periphery of the foci co-incident with RPA recruitment to the core 24,25. We measured the 189 
distribution of 53BP1 in foci associated with BRCA1 in BARD1 depleted cells complemented 190 
with WT or R99E-BARD1 protein. While the distribution of BRCA1 within IRIF in these cells was 191 
similar, in R99E-BARD1 complemented cells eviction of 53BP1 to the periphery was markedly 192 
reduced compared to WT-BARD1 complemented cells (Fig. 4D). Thus the ligase activity plays a 193 
role in 53BP1 repositioning at IRIF. 194 
 195 
 196 
Ligase activity in resection is needed after HR-commitment. 197 
Resection consists of an initiation step, requiring  the nuclease CtIP and Meiotic 198 
Recombination 11 Homolog A (MRE11) endonuclease activity, and an elongation stage which 199 
requires MRE11 exonuclease activity and then extension by Exonuclease 1 (EXO1) or Bloom 200 
Syndrome RecQ helicase, BLM and DNA replication helicase/nuclease 2 (DNA2) (reviewed in 201 
26). To assess where in resection the BRCA1-BARD1 Ub ligase activity is required we incubated 202 
cells with Bromodeoxyuridin (BrdU) and then measured track-lengths of exposed BrdU 203 
epitope, indicative of ssDNA as a measure of resected DNA after Olaparib exposure (after 204 
Cruz-Garcia et al., 2014  27). R99E-BARD1 complemented cells or BARD1 depleted cells 205 
showed shorter resection lengths. These were similar to cells exposed to MRE11 exonuclease 206 
inhibitor MIRIN  but not as severely truncated as those in cells exposed to the MRE11 207 
endonuclease inhibitor, PFM01 (Fig. 5A). These data suggest that some resection occurs in 208 
BRCA1-BARD1 ligase defective cells subsequent to the requirement for MRE11 endonuclease 209 
activity.  210 
 211 
Incomplete resection after commitment results in IR sensitivity which can be largely rescued 212 
by inhibiting resection initiation by depleting CtIP, since loss of CtIP prevents HR commitment 213 
but allows repair by NHEJ28. We found that depletion of CtIP improved repair of a NHEJ 214 
substrate, but not an HR substrate in BARD1 depleted cells (Fig 5B -D) and restored the 215 
majority of the resistance of R99E-BARD1 complemented or BARD1 depleted cells to IR (Fig 216 
5E).  These data functionally confirm that the requirement for BRCA1 ligase activity occurs 217 
after HR commitment. They also suggest that in BRCA1-BARD1 deficient cells, or in cells 218 
lacking its Ub ligase function, most sensitivity to IR is a consequence of incomplete resection 219 
and poor NHEJ, and a smaller proportion due to HR deficiency. 220 
 221 
 222 
An H2A-Ub fusion promotes DNA resection. 223 
We next assessed possible targets of BRCA1-BARD1 ubiquitination including 53BP1, its 224 
effector proteins and histones. We irradiated cells transfected with constructs expressing 225 
His-Myc-tagged Ub and BARD1 and purified covalently bound Ub-conjugates in highly 226 
denaturing conditions. 53BP1 and H2A were enriched in WT-BARD1 expressing cells but 227 
reduced in cells expressing R99E-BARD1 mutants (Fig. 6A), suggesting that BRCA1-BARD1 E3 228 
ligase activity results in ubiquitination of these two proteins. H2A-modification can be seen 229 
in the R99E-BARD1 lane on high exposure, indicating an additional, expected, BRCA1-BARD1 230 
independent modification. 231 
 232 
 233 
H2A has previously been identified as a BRCA1-BARD1 Ub ligase target 8,9,17, modified at C-234 
 terminal lysines K125, K127 and K1298. We attempted to replace a proportion of endogenous 235 
H2A (which is expressed from several genes) with mutant histone by generating stable cell 236 
lines bearing H2A-K125, 127 & 129 R. However, expression of the H2A mutants had no impact 237 
on Olaparib sensitivity, suggesting either modification elsewhere is important for resistance or 238 
insufficient mutant histone incorporation was achieved (Supplemental Fig. 6A & B). 239 
 240 
As an alternative approach we generated a H2A mutant-ubiquitin fusion protein, and 241 
addressed whether this can complement cells depleted of BARD1. In the H2A fusion 242 
lysines 13, 15, 118, 119, 125, 127 & 129 were mutated to arginines in order to 243 
interrogate the function of the fused Ub in the absence of endogenous ubiquitination 244 
events and the Ub itself was mutated at all 7 lysines to prevent chain formation. Both 245 
exogenous H2A and H2A-Ub fusion were incorporated into chromatin (Fig. 6B). In 246 
agreement with the finding that expression of a similar fusion improved repair of a gene 247 
conversion substrate in BRCA1-deficent cells9, we confirmed that expression of the H2A-248 
Ub protein promoted repair of a gene conversion substrate in BARD1 depleted cells 249 
(Supplemental Fig. 6C & D). To address whether H2A-Ub has the ability to restore 250 
physiological HR we examined the formation of RAD51 foci in BARD1 depleted cells. In a 251 
dose-response experiment we found that H2A-Ub levels correlated with RAD51 foci 252 
restoration, suggesting greater incorporation of the protein into chromatin resulted in 253 
greater rescue (Fig. 6C, Supplemental Fig. 6E). Moreover, neither the degree of gene 254 
conversion nor number of RAD51 foci in H2A-Ub expressing cells was further increased 255 
when 53BP1 was depleted (Supplemental Fig. 6D & F) indicating that H2A-Ub expression 256 
and the removal of 53BP1 have similar impacts. Consistent with an ability to 257 
complement the lack of BRCA1-BARD1 ligase activity in HR, expression of H2A-Ub 258 
promoted the survival of BARD1 depleted cells to Olaparib and Camptothecin but did 259 
not restore their resistance to HU (Supplemental Fig 6G-I), correlating with the 260 
requirement for BRCA1-BARD1 ligase activity. As anticipated both the drug resistance 261 
and restoration of RAD51 conferred by H2A-Ub required CtIP (Supplemental Fig 6J & K). 262 
Together these data provide strong evidence that the H2A-Ub fusion can restore 263 
physiological resection and HR in BARD1 depleted cells. 264 
 265 
 266 
We then examined the specifics of the H2A-Ub fusion in more detail. We tested an alternative 267 
globular protein, blue-fluorescent protein, BFP, genetically fused to the C-terminus of H2A. 268 
This fusion was unable to rescue drug resistance or restore RAD51 foci in BARD1 depleted cells 269 
(Fig. 6D, Supplemental Fig 6G & I) indicating that not all C-terminal protein fusions can 270 
complement. We addressed whether the location of the Ub might be critical and compared 271 
H2A (again bearing K to R mutations in 13, 15, 118, 119, 125, 127 & 129) in which Ub had been 272 
fused to the N-terminus, the C-terminus or both the C and N-termini. The N-terminal fusion of 273 
Ub to H2A slightly improved the numbers of RAD51 foci in BARD1 deleted cells whereas 274 
RAD51 foci in cells expressing H2A with Ub fusion to the C-terminus or to both ends were fully 275 
restored (Fig. 6D). These data suggest a C-terminal Ub fusion is most able to promote RAD51 276 
foci formation and that Ub fused to the N-terminus is not inhibitory to the restoration of HR 277 
promoted by the C-terminal fusion. Taken together these data indicate that incorporation of 278 
H2A-Ub into chromatin either supports a function similar to that of the BRCA1-BARD1 ligase or 279 
contributes an indirect role able to overcome the need for the heterodimer activity. 280 
 281 
 282 
We next addressed how BRCA1-BARD1 ligase activity or Ub-modified nucleosomes might 283 
 impact 53BP1 and resection. We assessed whether H2A-Ub fusions inhibit 53BP1 284 
accumulation to IRIF, whether BRCA1-BARD1 depletion results in expression of 285 
epigenetically silenced genes or whether depletion of a repressive chromatin factor, 286 
Chromodomain Helicase DNA Binding Protein 3(CHD3), part of the repressive Nucleosome 287 
Remodeling Deacetylase complex,  might relieve the requirement for BRCA1:BARD1 288 
(Supplemental Fig 7A-F). These potential mechanisms were unsupported by evidence from 289 
these investigations. 290 
 291 
 292 
SMARCAD1 is part of the BRCA1-BARD1 ligase pathway. 293 
We then focused on the proteins involved in the later-stages of DNA resection and noted 294 
reduced BLM recruitment to IRIF in BARD1 depleted cells (Supplemental Figure 7G). Unlike 295 
the requirement for BRCA1-BARD1 ligase activity, the requirement for late-stage resection 296 
enzymes in HR cannot be overcome by loss of 53BP129,30, leading us to consider the 297 
phenomenon of poor BLM recruitment as an indication of a defect earlier in the process. 298 
In yeast the ATP-dependent chromatin remodeler Function Unknown Now 30, Fun30, acts to 299 
promote Exo1 and Sgs1/BLM in resection31-33. The mammalian homologue, SMARCAD1 also 300 
promotes resection 32 and the protein has two Ubiquitin-binding CUE domains (similar to a 301 
domain in the yeast Cue1 protein)34 (Fig 7A). To test whether this protein might link BRCA1-302 
BARD1 dependent chromatin modification to 53BP1 repositioning and DNA resection, we 303 
examined interaction of the SMARCAD1 CUE domains with H2A-Ub bearing nucleosomes. 304 
Nickel beads bound to 6xHis-tagged SMARCAD1 CUE domains were able to purify H2A-Ub, 305 
but not H2A, whereas SMARCAD1-CUE-domain mutants (with Ub-contacting F, A & L residues 306 
previously described 35 changed to E, termed CUEm) purified neither histone (Fig 7B).  307 
 308 
We next addressed SMARCAD1 recruitment and introduced siRNA resistant plasmids 309 
encoding full-length SMARCAD1 or CUEm-SMARCAD1 into SMARCAD1 depleted cells (Fig. 310 
7C). WT-SMARCAD1 localized to laser-induced sites of DNA damage decorated with γH2AX 311 
(Fig. 7D). Its accumulation was reduced, but not lost, when BARD1 was depleted. Similarly 312 
the CUE- mutant showed reduced intensity at laser induced sites of damage compared to the 313 
WT protein (Fig. 7D). The recruitment of CUEm-SMARCAD1 was not reduced further by 314 
depletion of BARD1 suggesting BARD1 and the CUE domains affect SMARCAD1 accumulation 315 
through the same pathway (Fig. 7D). Pre-treatment of cells with KU55933, a specific inhibitor 316 
ATM inhibitor36, substantially diminished the formation of phosphorylated H2AX (γH2AX) 317 
from the path of the laser-line, and it also sustainably diminished SMARCAD1 accumulation 318 
(Fig. 7D). Thus although BRCA1-BARD1 and SMARCAD1 CUE domains support SMARCAD1 319 
recruitment, other ATM-dependent events are also required. 320 
 321 
We further tested the relationship between BRCA1-BARD1 and SMARCAD1. We found that 322 
although SMARCAD1 depletion alone reduced drug resistance and HR, this was not worsened 323 
in cells also without BRCA1-BARD1 activity (Supplemental Fig 8A &B), suggesting SMARCAD1 324 
and BRCA1-BARD1 ligase activity influence drug resistance through the same pathway. 325 
Moreover H2A-Ub expression was unable to restore RAD51 foci levels in BARD1 depleted cells 326 
that were also depleted of SMARCAD1 (Supplemental Fig 8C). This evidence points to a 327 
requirement for SMARCAD1 down-stream of BRCA1-BARD1 ligase activity and C-terminal H2A-328 
ubiquitination. Based on these data we predicted a similar function for SMARCAD1 in resection 329 
and HR as BRCA1-BARD1 and therefore examined the relationship with 53BP1 in resection and 330 
in IRIF. Loss of 53BP1 restored full BrdU resection lengths to SMARCAD1 depleted cells (Fig 7E) 331 
 suggesting an antagonistic relationship between SMARCAD1 and 53BP1 regulates resection. 332 
Further in S-phase or G2 cells depleted for SMARCAD1 we observed that 53BP1 was not evicted 333 
to the periphery of BRCA1-associated foci, indicating SMARCAD1 is also required for 53BP1 334 
repositioning (Fig. 7F). Expression of an siRNA resistant WT-SMARCAD1 protein restored 335 
normal distribution of 53BP1 but expression of the CUEm-SMARCAD1 or an ATPase-dead form 336 
(K528R) did not (Fig 7F and Supplemental Fig 8D), indicating both the CUE domains and 337 
enzymatic activity are required for repositioning 53BP1. Since the impact is not partial, these 338 
data also suggest that the CUE domains have a role in promoting 53BP1 repositioning beyond 339 
supporting accumulation of SMARCAD1 to sites of damage.  340 
 341 
In complementation of cells depleted for endogenous SMARCAD1 we found that CUEm-342 
SMARCAD1 was unable to restore RAD51 foci in IR-treated cells and neither CUEm-SMARCAD1 343 
nor the ATPase-dead mutant form could restore Olaparib or Camptothecin resistance of 344 
SMARCAD1 depleted cells (Fig 7G, Supplemental Fig 8E). Thus the SMARCAD1 CUE domains are 345 
vital to promote HR, correlating with their role in 53BP1 repositioning and drug resistance. As 346 
anticipated the need for the SMARCAD1 CUE-domains in promoting HR, measured by RAD51 347 
IRIF formation, was by-passed by treatment with siRNA to 53BP1 (Fig 7G). Similarly the 348 
repression of 53BP1 restored cellular Olaparib and Camptothecin resistance in cells depleted 349 
for SMARCAD1 (Fig 7H) confirming that SMARCAD1 is less important to cell survival when 350 
53BP1 is absent. Together these data confirm a link between BRCA1-BARD1 and SMARCAD1 in 351 
the promotion of resection in the presence of 53BP1. 352 
 353 
 354 
Discussion. 355 
Our data now provide some insight into how BRCA1 acts to inhibit the 53BP1-complex 356 
mediated block on resection. The BRCA1-BARD1 Ub ligase promotes a subset of DNA repair 357 
functions attributed to BRCA1 and participates in promoting resection steps after CtIP and 358 
MRE11-mediated commitment to HR. Consistent with the restoration of HR in BRCA1-BARD1 359 
deficient cells, we find that H2A-Ub complementation functions at the level of resection 360 
restoration. Initially we were surprised that our data indicates that C-terminal Ub modification 361 
of H2A is unlikely to directly inhibit the 53BP1 interactions. Instead we show that promotion 362 
of HR requires the Ub-binding CUE domains of the chromatin remodeler SMARCAD1. Critically 363 
both BRCA1 ligase activity and SMARCAD1 act to reposition 53BP1 within IRIF, correlating with 364 
the promotion of resection. 365 
 366 
Our data suggest to us a model in which the BRCA1-BARD1 ligase modifies chromatin which in 367 
turn promotes the accumulation and activity of the chromatin remodeler SMARCAD1 which 368 
then acts to mobilize 53BP1, allowing the completion of resection (Fig 8). By this means we 369 
suggest that BRCA1 activity promotes HR and inhibits toxic end-joining. Our model does not 370 
exclude an additional role for the 53BP1 ubiquitination that we observe but we note that H2A-371 
Ub is sufficient to restore HR to near normal levels in BRCA1-BARD1 deficient cells. 372 
Yeast Fun30 can both slide nucleosomes and evict histone H2A and H2B dimers37,38 so that 373 
whether SMARCAD1 shunts or removes DNA-damage proximal histones is not yet known. 374 
Conceptually, nucleosome sliding may be inhibited by upstream nucleosomes and eviction is a 375 
simpler model. In yeast histones remain bound to DSB ends longer in fun30Δ cells31. In either 376 
case, remodeled nucleosomes may be those loaded with 53BP1, or become refractory to 377 
53BP1 interaction. SMARCAD1 is also required in the re-establishment of silent 378 
 heterochromatin after DNA replication39. It will be intriguing to discover whether reduced 379 
SMARCAD1 activity at chromatin contributes to the reduced heterochromatin observed in 380 
Brca1 deficient murine cells9. 381 
We have shown that cell survival in response to some DNA damaging agents requires BRCA1 382 
ligase function to counter 53BP1, whereas the responses to other agents, which induce 383 
replicative stress or intra-strand cross-links, are independent of this pathway. This information 384 
may provide a rationale for tailored anticancer treatment for some BRCA1 mutation carriers 385 
since targeting ligase-dependent and independent aspects of the BRCA1 defect would be 386 
expected to slow the development of tumor resistance through 53BP1- complex down-387 
regulation or mutation. 388 
Several BRCA1 patient missense variants occur in the N-terminus with the potential to disrupt 389 
E3 Ub ligase function16. The role we have identified for the ligase activity in promoting HR is 390 
suggestive of a role in cancer protection. In defining the Ub-priming face of this and other 391 
Type-1 E3 Ub ligases our data provide a robust and novel means by which the ligase function 392 
can be assessed in cells and organisms. 393 
 394 
 395 
Acknowledgements 396 
Grant funding for this project was as follows. CRUK: C8820/A19062 (RMD, AG, HS, JB), 397 
C302/A14532 and C1206/A11978 (FZW, LHP), Breast cancer Campaign: 2010MayPR01 (JS), 398 
2013NovPR132 (S B-R). Engineering and Physical Sciences Research Council EP/L016346/1 (RN), 399 
University of Birmingham (AF, BJ and RMD). University of Sussex (RB): JRM, RN and NHK are 400 
HEFCE funded.  401 
We thank J. Stark (City of Hope) for U20S-DR3 and U20S-EJ5 cells and I-SCE1 plasmid, R. 402 
Everett, MRC Virology Unit, Glasgow for UBE2D1 cDNA, and Myc-His-Ubiquitin construct. 403 
T.Sixma and M. van Lohuizen, (both NKI Netherlands) for Ring1b159/Bmi1109 co-expression 404 
construct and BMI1-GFP. R. Goodman, Vollum Institute, Portland, OR.  HA-Rad18 was a kind 405 
gift from A. Zlatanou and the Flp-InTM Hela cells and MDC1 antibody were a generous gift from 406 
G. Stewart, both University of Birmingham, UK.  R. Katz (Fox Chase Cancer Centre, 407 
Philadelphia, PA, USA) for cryptic EGFP Hela cells and J. Tainer (The Scripps Research Institute, 408 
CA, USA) for PFM01 inhibitor.  Determination of the structure of the TRIM37 domain was supported 409 
by an NIH Protein Structure Initiative grant to G.T. Montelione, J.F. Hunt, and the Northeast Structural 410 
Genomics Consortium. We thank R. Hay for useful discussions and T. Sixma and M. Uckelmann 411 
for insights into the contribution of H2A-Ub interactions in purified nucleosomes. 412 
 413 
Author Contributions 414 
RMD performed structural analysis, generated proteins, performed cell and biochemical 415 
experiments, designed experiments and interpreted data. AG generated constructs and cell 416 
lines, and performed colony survival experiments. HS performed resection experiments and 417 
fluorescence microscopy. JS generated BARD1 cell lines and undertook immunoprecipitation 418 
experiments, RB performed high resolution BRCA1 and 53BP1 microscopy and analysis. AF 419 
generated RING1B-BMI1 proteins and performed biochemistry, BJ undertook foci 420 
quantitation. M D-M generated BRCA1 cell lines. S B-R and JB provided technical support and 421 
yeast experiments. LHP, RN, NHK and FW provided supervisory help and data interpretation. 422 
JRM and RMD wrote the paper. AG, HS and M D-M commented on the paper and on-going 423 
research. JRM contributed to data interpretation and directed the project. 424 
 425 
  426 
References. 427 
 428 
1. Long, D.T. & Walter, J.C. A novel function for BRCA1 in crosslink repair. Molecular cell 46, 111-2 429 
(2012). 430 
2. Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects 431 
Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106-16 (2012). 432 
3. Jiang, Q. & Greenberg, R.A. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 433 
290, 17724-32 (2015). 434 
4. Panier, S. & Boulton, S.J. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell 435 
Biol 15, 7-18 (2014). 436 
5. Bunting, S.F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by 437 
blocking resection of DNA breaks. Cell 141, 243-54 (2010). 438 
6. Escribano-Diaz, C. et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and 439 
BRCA1-CtIP controls DNA repair pathway choice. Mol Cell 49, 872-83 (2013). 440 
7. Brzovic, P.S. et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-441 
ligase complex. Proc Natl Acad Sci U S A 100, 5646-51 (2003). 442 
8. Kalb, R., Mallery, D.L., Larkin, C., Huang, J.T. & Hiom, K. BRCA1 is a histone-H2A-specific 443 
ubiquitin ligase. Cell reports 8, 999-1005 (2014). 444 
9. Zhu, Q. et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. 445 
Nature 477, 179-84 (2011). 446 
10. Sato, K. et al. A DNA-damage selective role for BRCA1 E3 ligase in claspin ubiquitylation, CHK1 447 
activation, and DNA repair. Current biology : CB 22, 1659-66 (2012). 448 
11. Reid, L.J. et al. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or 449 
homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci U S A 105, 20876-81 450 
(2008). 451 
12. Drost, R. et al. BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for 452 
Therapy Resistance. Cancer Cell 20, 797-809 (2011). 453 
13. Plechanovova, A. et al. Mechanism of ubiquitylation by dimeric RING ligase RNF4. Nature 454 
structural & molecular biology 18, 1052-9 (2011). 455 
14. Dou, H., Buetow, L., Sibbet, G.J., Cameron, K. & Huang, D.T. Essentiality of a non-RING element 456 
in priming donor ubiquitin for catalysis by a monomeric E3. Nature structural & molecular 457 
biology (2013). 458 
15. Metzger, M.B., Pruneda, J.N., Klevit, R.E. & Weissman, A.M. RING-type E3 ligases: Master 459 
manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochimica et biophysica 460 
acta (2013). 461 
16. Morris, J.R. et al. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to 462 
breast cancer susceptibility. Hum Mol Genet 15, 599-606 (2006). 463 
17. Mallery, D.L., Vandenberg, C.J. & Hiom, K. Activation of the E3 ligase function of the 464 
BRCA1/BARD1 complex by polyubiquitin chains. Embo J 21, 6755-62 (2002). 465 
18. Brzovic, P.S., Rajagopal, P., Hoyt, D.W., King, M.C. & Klevit, R.E. Structure of a BRCA1-BARD1 466 
heterodimeric RING-RING complex. Nature structural biology 8, 833-7 (2001). 467 
19. Ismail, I.H., McDonald, D., Strickfaden, H., Xu, Z. & Hendzel, M.J. A small molecule inhibitor of 468 
polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. The 469 
Journal of Biological Chemistry 288, 26944-54 (2013). 470 
20. Morris, J.R., Keep, N.H. & Solomon, E. Identification of residues required for the interaction of 471 
BARD1 with BRCA1. J Biol Chem 277, 9382-6 (2002). 472 
21. Boersma, V. et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' 473 
end resection. Nature (2015). 474 
22. Xu, G. et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. 475 
Nature (2015). 476 
23. Wang, J. et al. PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev 477 
28, 2693-8 (2014). 478 
24. Chapman, J.R., Sossick, A.J., Boulton, S.J. & Jackson, S.P. BRCA1-associated exclusion of 53BP1 479 
from DNA damage sites underlies temporal control of DNA repair. Journal of cell science (2012). 480 
25. Kakarougkas, A. et al. Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 481 
and RAP80 to resection. Nucleic acids research 41, 10298-311 (2013). 482 
26. Cejka, P. DNA End Resection: Nucleases Team Up with the Right Partners to Initiate 483 
 Homologous Recombination. J Biol Chem 290, 22931-8 (2015). 484 
27. Cruz-García, A., López-Saavedra, A. & Huertas, P. BRCA1 Accelerates CtIP-Mediated DNA-End 485 
Resection. Cell Reports 9, 451-459 (2014). 486 
28. Shibata, A. et al. Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in 487 
the maintenance of G(2)/M checkpoint arrest. Mol Cell Biol 30, 3371-83 (2010). 488 
29. Tomimatsu, N. et al. Exo1 plays a major role in DNA end resection in humans and influences 489 
double-strand break repair and damage signaling decisions. DNA Repair (Amst) 11, 441-8 490 
(2012). 491 
30. Grabarz, A. et al. A role for BLM in double-strand break repair pathway choice: prevention of 492 
CtIP/Mre11-mediated alternative nonhomologous end-joining. Cell reports 5, 21-8 (2013). 493 
31. Chen, X. et al. The Fun30 nucleosome remodeller promotes resection of DNA double-strand 494 
break ends. Nature 489, 576-80 (2012). 495 
32. Costelloe, T. et al. The yeast Fun30 and human SMARCAD1 chromatin remodellers promote 496 
DNA end resection. Nature 489, 581-4 (2012). 497 
33. Eapen, V.V., Sugawara, N., Tsabar, M., Wu, W.H. & Haber, J.E. The Saccharomyces cerevisiae 498 
chromatin remodeler Fun30 regulates DNA end resection and checkpoint deactivation. Mol Cell 499 
Biol 32, 4727-40 (2012). 500 
34. Neves-Costa, A., Will, W.R., Vetter, A.T., Miller, J.R. & Varga-Weisz, P. The SNF2-family member 501 
Fun30 promotes gene silencing in heterochromatic loci. PLoS ONE 4, e8111 (2009). 502 
35. Shih, S.C. et al. A ubiquitin-binding motif required for intramolecular monoubiquitylation, the 503 
CUE domain. Embo J 22, 1273-81 (2003). 504 
36. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the 505 
ataxia-telangiectasia mutated kinase ATM. Cancer Res 64, 9152-9 (2004). 506 
37. Byeon, B. et al. The ATP-dependent chromatin remodeling enzyme Fun30 represses 507 
transcription by sliding promoter-proximal nucleosomes. J Biol Chem 288, 23182-93 (2013). 508 
38. Awad, S., Ryan, D., Prochasson, P., Owen-Hughes, T. & Hassan, A.H. The Snf2 homolog Fun30 509 
acts as a homodimeric ATP-dependent chromatin-remodeling enzyme. J Biol Chem 285, 9477-510 
84 (2010). 511 
39. Rowbotham, S.P. et al. Maintenance of silent chromatin through replication requires SWI/SNF-512 
like chromatin remodeler SMARCAD1. Mol Cell 42, 285-96 (2011). 513 
40. Buchwald, G. et al. Structure and E3-ligase activity of the Ring-Ring complex of polycomb 514 
proteins Bmi1 and Ring1b. The EMBO journal 25, 2465-74 (2006). 515 
41. Huang, A. et al. Symmetry and asymmetry of the RING-RING dimer of Rad18. J Mol Biol 410, 516 
424-35 (2011). 517 
42. Kuzin, A., Chen, Y., Seetharaman, J., Mao, M., Xiao, R., Ciccosanti, C., Shastry, R., Everett, J.K., 518 
Nair, R., Acton, T.B., Rost, B., Montelione, G.T., Tong, L., Hunt, J.F.  519 
43. Kappo, M.A. et al. Solution structure of RING finger-like domain of retinoblastoma-binding 520 
protein-6 (RBBP6) suggests it functions as a U-box. J Biol Chem 287, 7146-58 (2012). 521 
 522 
 523 
Figure Legends. 524 
Uncropped blot images can be found in Supplementary Data Set 1 and source data for 525 
the graphs can be found in Supplementary Source Files Figs 1-7. 526 
 527 
 528 
Figure 1. A basic residue of BARD1 promotes Ub-transfer from BRCA1-E2~Ub 529 
 530 
A. Western blots comparing the ability of BRCA1-BARD1 heterodimer containing Wild type 531 
(WT) WT-BARD1 or R99E-BARD1 to catalyse the formation of Ub chains. Ub mix refers 532 
to E1, E2, Ub, ATP and ligase reaction buffer. Probed for BRCA1, 6xHis (BARD1) and Ub. 533 
B. Yeast two hybrid assays showing the BRCA1-BARD1 heterodimer is not disrupted by 534 
BARD1-R99 variants.  Yeast strains expressed VP16-BRCA1 1-300 with WT and 535 
substituted LexA-BARD1 27-146 (100 mM 3AT). L44R is included as a heterodimer-536 
disruptive control [19]. 537 
 C. Top, western blots showing improved activity of R99E-BARD1 heterodimer with D32R 538 
mutant Ub. Graph below shows quantification of high molecular weight Ub from 4 539 
independent experiments, bars are s.e.m (Note R99E-heterodimer reaction exposed 540 
longer than control). * indicates p<0.05, Student’s t-test throughout. 541 
D. In vitro assays showing ability of WT and R99E-BARD1 heterodimers to discharge Ub 542 
from a loaded E2~Ub dimer. Results show mean and s.e.m from 4 independent 543 
experiments.  544 
 545 
Figure 2. Other Type-I RING E3 ligases require R or K residues on the partner protomer. 546 
A. Structural models showing views in the same orientation of Type 1 RING:RING 547 
structures: BRCA1-BARD1 (PDB: 1JM7 ref 18) with BMI1-RING1B (PDB: 2CKL ref 40), 548 
RAD18 (PDB:2Y43 ref 41), TRIM37 (PDB:3LRQ42), and RBBP6 (PDB:3ZTG ref 43), residues 549 
equivalent to R99-BARD1 are shown in pink. 550 
B. Western blot indicating the ability to induce mono-ubiquitination of PCNA is lost by 551 
R76A-RAD18. Cells transfected with either WT-RAD18 or R76A-RAD18 mutant in 552 
otherwise untreated 293 cells or those treated with 40 J UV. Lysates were probed for 553 
PCNA and controls as shown. 554 
C. Western blots indicating mono-ubiquitination of H2A in nucleosomes by incubation 555 
with WT BMI1-RING1B and K73E-BMI1 bearing RING1B heterodimer.  556 
 557 
 558 
Figure 3. BRCA1-BARD1 ligase activity promotes survival to a subset of DNA damaging 559 
agents.  560 
A. Structural model BARD1 (orange) and BRCA1 (green) (PDB: 1JM7) illustrating the location 561 
of L44 (blue) and R99 (pink) residues. Zinc ions are filled spheres (black). Lower image is 562 
90o rotation about the horizontal. 563 
B. Immunoblot of cells treated with Non-targeting control siRNA (NTC) or BARD1 siRNA and 564 
complemented with siRNA-resistant BARD1 variants shown. The graphs show cell survival 565 
relative to NTC control of cells depleted and complemented in this way were exposed to 566 
the agents shown, plated and clones counted 10-14 days later. Colony numbers are 567 
expressed as % of untreated cells. 4 replicates per experiment and means from minimum 568 
of 3 experiments shown, bars are s.e.m. 569 
C. As in B, depleted with siRNA to BRCA1 and complemented with siRNA resistant WT-BRCA1 570 
and I26A-BRCA1. 4 replicates per experiment, 4 experiments, bars are s.e.m.  571 
 572 
Figure 4. BRCA1-BARD1 ligase activity promotes DNA resection in the presence of 53BP1. 573 
A. RPA and RAD51 foci in EdU positive cells treated with BARD1 siRNA and complemented 574 
with siRNA resistant WT, R99E- or L44R-BARD1 variants. Images show representative cells. 575 
Scale bars are 10 μm throughout. Graphs (right) show the mean number of foci per cell 576 
RPA = 60 cells, Rad51 = 100 cells, bars are s.e.m. ***p<0.005. 577 
B. The graph shows colony cell survival in Olaparib (10 μM) relative to NTC control of cells 578 
treated with BARD1 siRNA and complemented with WT or R99E-BARD1 and treated with 579 
additional siRNAs shown.  3, replicates per experiment, 4 experiments, bars are s.e.m. 580 
*p<0.05. Western blots (right) show detection of BARD1, CtIP and 53BP1 in treated cells. 581 
C. Graph shows colony survival of BRCA1 depleted cells and cells co-depleted with 53BP1 and 582 
treated with Hydroxyurea (3 mM) relative to NTC treated controls. 3 replicates per 583 
 experiment, 3 experiments, bars are s.e.m. * indicates p<0.05. Western blots (right) show 584 
detection of 53BP1, BRCA1 in treated cells.  585 
D. High-resolution images of BRCA1 and 53BP1 in cells treated with BARD1 siRNA and 586 
complemented with WT- or R99E-BARD1, exposed to 2 Gy IR and fixed 8 hours later. An 587 
average across 30 profiles is shown, over 3 experimental repeats. Bars =1 standard 588 
deviation. 589 
 590 
Figure 5. BRCA1-BARD1 ligase activity is required after HR-commitment. 591 
A. BrdU track lengths in cells were treated with BrdU, and Olaparib (10 µM). 50 fibres, 592 
horizontal line represents mean, bars= s.e.m. ***p<0.005. 593 
B. Graph shows quantification of GFP recovery in NHEJ-substrate cells depleted for BARD1 594 
and transfected with siRNA resistant variants,  3 replicates per experiment, 4 experiments, 595 
bars are s.e.m ***= p<0.005.  596 
C. Graph shows quantification of GFP recovery in NHEJ-substrate cells depleted for BARD1, 597 
CtIP or both 3 replicates per experiment, 6 experiments, bars are s.e.m ***= p<0.005. 598 
D. Graph shows quantification of GFP recovery in HR-substrate cells depleted for BARD1, CtIP 599 
or both. 3 replicates per experiment, 6 experiments, bars are s.e.m ***= p<0.005. 600 
E. Graph shows colony survival of cells treated with IR (0.5 Gy) and depleted for BARD1 and 601 
complemented with WT or R99E-BARD1 or co-depleted for BARD1 and CtIP relative to 602 
control treated cells. 3 replicates per experiment, 3 experiments, bars are s.e.m ***= 603 
p<0.005. 604 
 605 
 606 
Figure 6. BRCA1-BARD1 dependent modification of nucleosomes. 607 
A. Western blot of selected proteins in whole cell extracts (WCE) and Nickel-column 608 
precipitations (Ni2+ IP) of lysates from cells transfected with His-Myc-Ub and BARD1 609 
constructs and irradiated (30 Gy). 610 
B. Western blot of HA-H2A of cells transfected with HA-H2A or HA-H2A-Ub fusion. In the 611 
fusion Histone 2A carried lysine to arginine mutations at lysines K13 15 118 119 125 127 612 
and 129 and in the Ub the seven lysines of Ub were mutated to R (illustrated top). Cells 613 
were lysed sequentially in buffer containing increasing amounts of salt. Sol = soluble 614 
fraction Nuc= nuclear fraction and Pel= Pellet. 615 
C. Quantification of HA-H2A-Ub intensity (expression) and number of RAD51 foci in BARD1 616 
depleted S-phase cells after exposure to IR (5 Gy) and 2 hours recovery (for representative 617 
immunofluorescence images see Supplemental Fig 6E) n=30 cells. Western blots (right) 618 
shows BARD1 and HA-H2A-Ub expression in treated cells. 619 
D. Graph below shows quantification of RAD51 foci in BARD1 depleted cells expressing HA-620 
H2A or various fusions of H2A and pulsed with EdU fixed 2 hours after 5 Gy IR.  n=75 cells 621 
per condition from 3 experiments, bars= s.e.m. Images top show cells stained with RAD51, 622 
HA and incubated with click-it detection reagents to detect EdU labelled S-phase cells.  623 
 624 
Figure 7. The nucleosome remodeler SMARCAD1 is in the same pathway as BRCA1-BARD1 625 
ligase activity. 626 
 A. Illustration of SMARCAD1 protein. 627 
B. Western blot showing the detection of HA-H2A (WT) or H2A-Ub expressed in cells and 628 
bound, or not bound, to in vitro purified WT or mutant SMARCAD1 CUE domains (amino 629 
acids 98-318). 630 
C. Western blot showing expression of full length WT and CUE-domain mutant SMARCAD1 in 631 
SMARCAD1 depleted cells.  632 
D. Representative images (left) of cells expressing siRNA resistant SMARCAD1 variants treated 633 
with SMARCAD1 siRNA or co-depleted with siRNA to BARD1 and bearing laser-line induced 634 
DNA damage. Cells labelled ATMi = 10 μM KU55933 ATM inhibitor 4 hours prior to 635 
damage. White ‘X’ marks the laser-line path. The graph shows intensity of myc-SMARCAD1 636 
measured in the region of the γH2AX laser line compared to nucleoplasm intensity. 25 lines 637 
per experiment, 2 experiments, bars S.E. **= p<0.05, ***= p<0.005 Student t-test. Scale  638 
bars 10 µm 639 
E. Length of BrdU DNA fibres after treatment with Olaparib (10 µM) in cells treated with the 640 
siRNAs shown. Western blots (right) shows detection of BARD1 and SMARCAD1 proteins in 641 
treated cells. 642 
F. Representative images (left) of cells transfected with siRNA targeting SMARCAD1 with 643 
siRNA resistant WT and CUEm myc-SMARCAD1 exposed to 2 Gy IR and fixed 8 hours later. 644 
Graphs (right) show averages of 30 foci profiles over 3 experimental repeats. Bars =1 645 
standard deviation.  646 
G. Quantification RAD51 foci in cells transfected with SMARCAD1 and 53BP1 siRNA together 647 
with siRNA resistant forms of SMARCAD1, n=70 cells, bars= s.e.m. ***p<0.005).   648 
H. The graph shows colony cell survival in Olaparib (10 μM) and Camptothecin (2.5 μM) 649 
relative to NTC control of SMARCAD1 complemented cells, 3 replicates per experiment, 6 650 
experiments, bars are s.e.m. p<0.005. Western blots (right) show detection of SMARCAD1 651 
and 53BP1 in treated cells. 652 
 653 
Figure 8. Proposed model for the BRCA1-BARD1 Ub ligase in promoting resection at DSB-654 
damaged chromatin. 655 
1. Limited resection occurs in the absence of BRCA1-BARD1 activity dependent on CtIP-656 
Mre11. 657 
2. BRCA1-BARD1 dependent Ub modification of H2A promotes SMARCAD1 interaction with 658 
damage-proximal nucleosomes. 659 
3. SMARCAD1 activity to reposition or evicts nucleosome, and move 53BP1 and its effector 660 
proteins to release 53BP1-mediated inhibition of DNA resection. 661 
4. Long range resection can proceed. 662 
 663 
Online Methods  664 
 665 
Western blots show a representative image taken from >3 independent experiments unless 666 
otherwise specified. A full list of primers, siRNA sequences and antibodies used can be found 667 
in Suppl. Tables 1-3. All constructs and mutations generated in-house by site-directed 668 
mutagenesis were confirmed by sequencing (Source Biosciences). All chemicals, unless 669 
otherwise stated are from Sigma or Fisher. 670 
  671 
Yeast Two and Three hybrid Assays. The yeast expression vectors used contained human 672 
BRCA1-N-terminal amino acids 2–300 expressed as a fusion with the transactivation domain 673 
VP16 (pVP16-BRCA1), and full length E2 ubiquitin conjugating enzyme, human UBE2D1, or 674 
BARD1 amino acids 27-146, expressed as fusions with the DNA-binding protein LexA (pLexA). 675 
For three-hybrid studies pY3H-Ade2 was generated from pY3H (Dualsystems Biotech) by 676 
cloning the Ade2 gene into Sbf1 and Stu1 sites which resulted in destruction of the original 677 
Ura2 selection gene. Full length BARD1 was cloned into pY3H-Ade2 vector by Genscript. 678 
Growth on increasing concentrations of 3-Amino-1,2,4-triazole (3-AT) a competitive inhibitor 679 
of the product of the HIS3 gene, indicate greater transcriptional production of HIS3. 680 
 681 
BRCA1-BARD1 protein production. For bacterial expression of human BRCA1:BARD1 682 
heterodimer a bi-cistronic expression vector encoding six histidine-tagged BRCA1 amino acids 683 
1–300 and six histidine-tagged BARD1 amino acids 26–142 was generated by amplification of 684 
human BRCA1 and BARD1 cDNA templates and cloned into pET15b. Mutations were made by 685 
site-directed mutagenesis in BRCA1 or BARD1. Proteins were purified as described previously 686 
16. In brief, BRCA1 and BARD1 proteins were expressed in BL21-DE3 bacteria (Bioline). Bacteria 687 
were grown at 37 oC until optical density 0.6 was reached. Protein expression was induced by 688 
addition of 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG)(Bioline) and the temperature 689 
immediately reduced to 25 oC. Bacteria were grown for a further 24 hours. A bacterial pellet 690 
was collected following centrifugation at 3000g for 10 min, 4 oC and then lysed in ice cold lysis 691 
buffer (50 mM sodium phosphate, pH7, 300 mM sodium chloride, 5 % glycerol, 10 mM beta-692 
mercaptoethanol). The lysate was sonicated for 1 min at 30 % intensity and then clarified by 693 
centrifugation at 14,000 g, 10 min, 4 oC. The supernatant was incubated with 0.25 ml His-select 694 
beads (Sigma) overnight at 4 oC with rotation. The following day the beads were washed with 695 
three ten minute washes in ice cold wash buffer (50 mM sodium phosphate, pH7, 300 mM 696 
sodium chloride, 5 % glycerol, 10 mM beta-mercaptoethanol, 50 mM imidazole) before eluting 697 
on ice in elution buffer (50 mM sodium phosphate, pH7, 300 mM sodium chloride, 5 % 698 
glycerol, 10 mM beta-mercaptoethanol, 300 mM imidazole) . Purified proteins were dialyzed 699 
against (25 mM TRIS-HCl, pH7.5, 10 % glycerol, 2 mM dithiothreitol (DTT), 150 mM potassium 700 
chloride) and purity checked by resolution on 15% SDS-PAGE gel.  701 
 702 
BMI1-RING1B protein production. Ring1b159-Bmi1109 construct (a kind gift of Titia Sixma, NKI 703 
Netherlands) was co-expressed in E. coli BL21 (DE3) with both genes on a single promoter and 704 
a glutathione-S-transferase (GST) fusion tag on the RING1B fragment only. After co-purification 705 
on Glutathione Sepharose columns and washing, the dimer was eluted by cleaving with 706 
PreScission protease (after Buchwald et al 2006 40). Protein purity was checked by resolution 707 
on 15% SDS-PAGE gel. 708 
 709 
Wild-type and D32R-Ub protein production. Synthetic yeast ubiquitin was cloned into 710 
pGEX2TK, before site directed mutagenesis to generate D32R. Constructs were expressed in 711 
BL21 cells (Bioline) and grown at 37 oC to an OD of 0.6 before inducing protein expression with 712 
0.5 mM IPTG. Bacteria were grown for a further 16 hours before lysis (20 mM Tris-HCl pH 8, 713 
130 mM sodium chloride, 1 mM EGTA, 1.5 mM magnesium chloride, 1 % Triton x100, 10% 714 
glycerol, 1 mM DTT and Protease Inhibitors (Complete Protease Inhibitor tablets – Roche). The 715 
lysate was sonicated for 1 min at 30 % intensity and then clarified by centrifugation at 14,000 716 
g, 10 min, 4 oC. The supernatant was incubated with 0.25 ml glutathione sepharose-4B beads 717 
 (GE Healthcare) overnight at 4 oC with rotation. The following day the beads were washed with 718 
three ten minute washes in ice cold lysis buffer before a final wash in thrombin cleavage buffer 719 
(20 mM TRIS pH 8.4, 150 mM sodium chloride, 2.5 mM calcium chloride). Ubiquitin was eluted 720 
from the beads by cleaving the GST-tag with 2 Units of thrombin (Promega) overnight at 4 oC. 721 
The following day the supernatant was incubated with 50 ul p-aminobenzamidine-agarose 722 
(Sigma) for 2 hours to remove Thrombin before dialysis against (25 mM TRIS-HCl, pH7.5, 10 % 723 
glycerol, 2 mM dithiothreitol (DTT), 150 mM potassium chloride). 724 
 725 
SMARCAD1-CUE domain protein production and pull downs. Codon optimized SMARCAD1-726 
CUE domains (amino acids 98-318) WT and CUEm (L168E F169E L195E L196E F263E A285E 727 
L286E) were custom synthesized by Genscript and sub-cloned into pET15b. The CUE domains 728 
were expressed in BL21-DE3 bacteria and purified onto Nickel beads as described for BRCA1-729 
BARD1 protein production. Nickel beads bound by CUE domains were stored in PBS for short 730 
term pull down experiments.  731 
Lysates were prepared from HeLa Flp In stable cell lines (Empty, HA-H2A or HA-H2A-Ub cell 732 
lines) which had been induced with Doxycycline (1 μg/ml) for 72 hours to allow protein 733 
expression and chromatin incorporation of the HA-H2A constructs. Cells were lysed in 20 mM 734 
Tris pH8, 137 mM NaCl, 1 mM EGTA, 1.5 mM MgCl2, 1 % TritonX100, 10 % Glycerol with the 735 
addition of Protease Inhibitors (Complete Tablets – Roche), Phosphatase Inhibitors (PhosSTOP 736 
– Roche), 10 mM Iodoacetimide and 4 mM N-Ethylmaleimide. DNAse1 (0.1 mg/ml) was added 737 
for 30 mins on ice before centrifugation and incubation with His-beads or His-CUE domain 738 
beads overnight at 4 oC. Samples were washed 4x with ice-cold PBS, resuspended in SDS-PAGE 739 
loading buffer and resolved by western blotting.  740 
 741 
Ubiquitin ligase assays. Ubiquitin conjugation assays were performed as described 44. Ligase 742 
assays were carried out in 50 mM Tris-HCl (pH 7.5), 50 mM sodium chloride, 5 mM ATP. The 743 
precise concentrations of the proteins and the reaction conditions used varied over the 744 
following ranges: 100 ng E1, 25 ng UBE2D1-3 enzymes (Viva Biosciences, Exeter UK) and 2.5 μg 745 
ubiquitin (Sigma), and ~ 30 ng of ligase proteins. The mixtures were incubated at 37°C (BRCA1-746 
BARD1) or 30°C (BMI1-RING1B) for 30 to 60 min and then stopped with 3x gel-loading buffer, 747 
subjected to electrophoresis and western blotting for Ubiquitin (P4D1) and BRCA1 (MS110).  748 
Note for comparison of WT and R99E-BARD1 containing heterodimers, with mutant D33R Ub 749 
the WT complexes were incubated for 15 minutes, the mutant reactions for 1 hour. In 750 
reactions examining nucleosome modification 0.05 μg nucleosomes (Cambridge Bioscience) 751 
was added per reaction as described above. 752 
 753 
Ub-Transfer Reactions. E2 (UBE2D1, 3) was first charged with ubiquitin in the absence of an E3 754 
and a substrate. To prepare the UBE2D1~Ub thioester, we incubated UBE2D1 and ubiquitin 755 
(both 100 μM) with 0.2 μM Ube1 in 50 mM Tris, 150 mM NaCl, 3 mM ATP, 5 mM MgCl2, 0.5 756 
mM TCEP and 0.1% (v/v) NP40 (pH 7.5) at 37 °C for 12 min. To stop E1-mediated loading of E2 757 
with ubiquitin, we depleted ATP by adding apyrase (4.5 U ml−1; New England BioLabs). The 758 
E2~Ub thioester (~20 μM) was incubated with BRCA1-BARD1, ~ 30 ng, and 500 mM lysine at 759 
room temperature. Reactions were stopped by addition of non-reducing SDS-PAGE loading 760 
buffer. The percentage of E2 modified with ubiquitin was determined by quantification of 761 
scans using ImageJ software. Reaction time points were taken from 30 s to up to 20 min, and 762 
reaction rates were determined using at least three time points within the linear range of the 763 
 reaction.  764 
 765 
Interrogation of protein structures. The RING domain of BRCA1 (PDB 1JM7 chain A)18 was 766 
superimposed on the RING domain of RNF4 RING–UBE2D1(S22R/C85K)–Ub complex (PDB 767 
4AP4)13 using Swiss PDB-viewer. Structural representations and models were generated using 768 
PyMol (Schrödinger). Similarly the RING domain of BARD1 (PDB 1JM7 chain B) was 769 
superimposed on the RING domains of BMI1-RING1B (PDB: 2CKL)40, RAD18 (PDB: 2Y43)41, 770 
TRIM37 (PDB:3LRQ)42 and RBBP6 (PDB:3ZTG)43 to identify residues similarly located to BARD1-771 
R99. 772 
 773 
Cell lines. Flp-InTM  Doxycyclin inducible Hela parent cell line was a kind gift of G. Stewart, 774 
University of Birmingham UK and Flp-InTM  T-Rex Doxycyclin inducible 293 cell lines (Life 775 
Technologies) were grown in DMEM (Sigma), 10 % Tetracycline-Free Fetal Calf serum 776 
(Clontech) supplemented with 1 % penicillin/streptomycin. All other cell lines were grown in 777 
DMEM supplemented with 10% fetal calf serum (Sigma) and 1 % pen/strep. The pCMV-EGFP 778 
and pEF-GFP HeLa cell lines were a kind gift of R. Katz (Fox Chase Cancer Centre, Philadelphia, 779 
PA, USA). The 293T cells have been authenticated at source, the HeLa lines have not. 780 
Mycoplasma testing by Hoechst DNA staining. 781 
 782 
BARD1 expressing lines: pcDNA5/FRT/TO-RFP-Flag-BARD1 (human) was engineered to carry 783 
silent mutations to confer siRNA resistance (WT seq: TGGTTTAGCCCTCGAAGTAAG; siRNA 784 
resistant sequence: TGGTTTtcgCCaCGtAGTAAG) and was synthesized by Genscript for WT and 785 
L44R variants. The R99E mutation was later introduced by site-directed mutagenesis and 786 
confirmed by sequencing. Stable cell lines containing Tet-inducible RFP-Flag-BARD1 were 787 
generated in Flp-InTM Hela and 293 cells by co-transfection of the pcDNA5/FRT/TO-RFP-Flag-788 
BARD1 constructs with the recombinase pOG44 (Invitrogen) using FuGene6 (Promega). After 789 
48 hours, cells were placed into Hygromycin selection media (400 μg/ml) and grown until 790 
colonies formed on plasmid-transfected plates but not controls. For protein expression cells 791 
were incubated +/- Doxycyclin (1 μg/ml) for 48 hours and positive clones were selected by 792 
screening for Flag expression by western blot. Expression level in the clonal cell population 793 
was confirmed by immunofluorescence for RFP. Flp-InTM 293 T-REx inducible cells expressing 794 
BARD1 derivatives were generated from pcDNA5-RFP-Flag-BARD1, recombined as described. 795 
 796 
BRCA1 expressing lines: Flag-EGFP-BRCA1 (human) inducible Flp-InTM Hela cells expressing WT 797 
and BRCA1 mutants were generated by cloning Flag-EGFP-BRCA1 into pcDNA5/FRT/TO, before 798 
recombination and selection as described for BARD1 expressing lines. 799 
 800 
H2A-Ub fusion expressing lines. Human HIST1H2AC was cloned in frame with an N terminal 801 
HA tag in pCDNA3.1+ by GenScript. Where indicated, individual lysines were mutated to 802 
arginine residues by gene synthesis. Human ubiquitin (UBA52) was positioned at the N 803 
terminus and/or C terminus of H2A with the addition of N terminal HA tags. cDNA for ubiquitin 804 
was mutated at each of the seven lysine residues to arginine to prevent chain formation. The 805 
sequence of all constructs was verified by GenScript. Flp-InTM Hela cells expressing H2A 806 
mutations and fusions were generated by cloning into pcDNA5/FRT/TO, (H2A-WT using 807 
HindIII:Xho1 and H2A-Ub using Hind III: BamH1), H2A-BFP was cloned directly into pcDNA5, 808 
before recombination and selection as described for BARD1 expressing lines. 809 
 Myc-SMARCAD1 expressing lines. Human SMARCAD1 cDNA was cloned in frame with a N 810 
terminal myc tag into pCDNA5/FRT/TO by gene synthesis (GenScript). The cDNA was rendered 811 
siRNA resistant to the two siRNA used in this study with the following silent mutations 812 
(indicated in red).  813 
siRNA #1 resistance 814 
      gaa aga gat gta gtt ata agg ctt atg aac 815 
 451   E      R     D   V    V     I     R     L    M   N  816 
     gaa aga gac gtc gtc att cgc ctg atg aac 817 
451    E      R     D   V    V     I     R    L     M   N 818 
 819 
 820 
siRNA #2 resistance 821 
      agc caa ggg acg att gaa gaa tcc atg cta a 822 
981     S   Q    G     T     I     E     E     S     M   L   823 
       agc caa ggc aca atc gag gag agc atg cta a 824 
981      S    Q    G     T     I     E     E      S    M   L   825 
 826 
The following mutations were introduced to generate the CUE 1+2 mutant; L168E, F169E, 827 
L195E, L196E (CUE1) and F263E, A285E, L286E (CUE2). The ATPase mutant (K528R) was made 828 
by site-directed mutagenesis and confirmed by sequencing. 829 
 830 
Transfections. siRNA transfections were carried out using Dharmafect1 (Dharmacon) and DNA 831 
plasmids using FuGENE 6 (3 µl:1 µg FuGENE:DNA) (Promega) following the manufacturer’s 832 
guidelines. 833 
DNA repair reporter assays. DR3 and EJ5 U20S reporter cell lines were simultaneously co-834 
transfected with siRNA using Dharmafect1 (Dharmacon) and DNA (RFP or RFP-BARD1 and I-835 
Sce1 endonuclease expression constructs) using FuGene6 (Promega) respectively. After 16 836 
hours the media was replaced and cells were grown for a further 48 hours before fixation in 837 
2% PFA. RFP and GFP double positive cells were scored by FACS analysis using a CyAn flow 838 
cytometer and a minimum of 10000 cells counted. Data was analyzed using Summit 4.3 839 
software. Each individual experiment contained 3 technical repeats and normalized to siRNA 840 
controls or to WT-complemented cells. Graphs shown are combined data from a minimum of 3 841 
independent experiments and error bars show standard error. H2A and H2A-Ub fusion 842 
constructs were co-transfected with I-Sce1 and RFP as a surrogate marker for transfection 843 
efficiency.  844 
 845 
Colony Assays. Cells were plated at 2 x 105 cells/ml in a 24 well plate and treated as required. 846 
Cells were then trypsinized transferred to a 6 well plate (volume transferred based on plating 847 
density experiments). Plates were incubated for 10-14 days. Colonies were stained using 0.5% 848 
crystal violet (BDH Chemicals) in 50% methanol and counted. Each individual experiment 849 
contained 3 technical repeats and is normalized to untreated controls. Graphs shown are 850 
combined data from a minimum of 3 independent experiments and error bars show standard 851 
error. 852 
 853 
DNA damaging agent exposures: Cells were exposed to irradiation using a Gamma-cell 1000 854 
Elite irradiator (caesium-137 source). Cells were exposed to Hydroxyurea overnight before 855 
 plating.  For all other drugs, cells were exposed for 2 hours. Camptothecin, etoposide, 4AN, 856 
hydroxyurea, aphidicolin, and cisplatin were from Sigma. Olaparib was from Selleck chemicals. 857 
 858 
Laser Microirradiation. Laser-microirradiation experiments were performed on BrdU-859 
presensitized cells (10μM BrdU, 24h) as described45 using a Zeiss PALM MicroBeam equipped 860 
with a 355 nm UV-A pulsed-laser and the 40 x objective with laser output at 40%, assisted by 861 
the PALMRobo-Software supplied by the manufacturer. 862 
 863 
Modified Measurement of resection tracks (BrdU). 24 hours before fixation cells were 864 
incubated with 10 µM BrdU and then 10 µM Olaparib for the last 16 hrs of treatment. Cells 865 
were trypsinized and resuspended in ice cold PBS to a concentration of 10 x 105 cells/ml. In 866 
order to lyse the cells, 2 µl of sample was placed on a slide and mixed with 7 µl of spreading 867 
buffer (200 mM Tris pH 7.4, 50 mM EDTA, 0.5% SDS) and incubated for 2 mins. Slides were 868 
then placed at a shallow angle to cause the droplet to gradually run down the slide, ensuring 869 
constant movement of the droplet. Slides were then fixed in 3:1 MeOH: AcOH for 10 mins and 870 
then stored at 4°C. 871 
Slides were washed in PBS and Blocking solution (2g BSA, 200 µl Tween 20, 200 ml PBS) and 872 
then incubated with mouse anti BrdU primary antibody. Slides were then incubated with 873 
AlexaFluor Rabbit anti mouse 488. Images were taken on the Leica DM6000B microscope and 874 
analysis performed using ImageJ software. Lengths were calculated using a scale bar to 875 
convert pixels to µm and this ratio, of 3.493 pixels per µm, was used to measure BrdU track 876 
lengths. 50 fibers per treatment were measured and plotted on a Whisker plot using 877 
Graphpad. 878 
Immunoprecipitation. BARD1-Flp-InTM 293 cells were Doxycyclin (1µg/ml) treated for 48 hours 879 
and lysed in cold Nuclear Lysis Buffer (10 mM HEPES pH7.6, 200 mM sodium chloride, 1.5 mM 880 
magnesium chloride, 10% glycerol, 0.2 mM EDTA, 1% Triton). For every 10 ml of nuclear lysis 881 
buffer, 1 Complete protease inhibitor tablet, 1 PhosSTOP phosphatase inhibitor tablet (Roche), 882 
and 1 µl DNase were added. Pre-cleared lysate combined with washed Flag-agarose beads 883 
(Sigma) was incubated with rotation overnight at 4°C. After 3 x 1 ml PBS-0.02% Tween washes, 884 
all wash buffer was removed before either adding 2 x loading buffer, boiled and loaded onto 885 
an SDS PAGE gel and analyzed by western blotting or used for an E3 ligase assay. 886 
Nickel-precipitations. (Enrichment of Ubiquitin-conjugates). Cells transfected with Hisx6-myc-887 
Ubiquitin were lysed directly in 8 M urea buffer (8 M Urea, 0.1 M sodium phosphate pH6.3, 888 
0.01 M Tris–HCl pH 6.3, 10 mM β-mercaptoethanol, 5 mM imidazole plus 0.2% Triton-X-100) 889 
harvested and sonicated. They were then mixed with His-Select beads (Sigma) and incubated 890 
overnight at 4 °C, washed and eluted in sample loading buffer. 891 
 892 
Immunofluorescence. Cells were plated on 13 mm circular glass coverslips at a density of 5 x 893 
104 cells/ml, treated as required. For RPA, BLM and RAD51 staining cells were pre-extracted in 894 
CSK buffer (100 mM sodium chloride, 300 mM sucrose, 3 magnesium chloride, 10 mM PIPES 895 
pH 6.8) for 1 minute at room temperature, For all other staining cells were first fixed in 4% PFA 896 
and permeabilized with 0.2% TritonX100 in PBS. After blocking in 10% FCS, cells were 897 
incubated with primary antibody for 1 hr (unless otherwise stated) and with secondary 898 
AlexaFluor antibodies for 1 hour. The DNA was stained using Hoechst at 1:20,000. In some 899 
images the DNA stain has been drawn around (but not shown) to illustrate the location of the 900 
 nucleus. 901 
EdU staining. Cells were incubated with the nucleoside analogue EdU (5-ethynyl-2'-902 
deoxyuridine) at 10 µM final concentration for 2 hours (RAD51/RPA experiments) or 1 hour 903 
super-resolution imaging prior to fixation. Staining was carried it out following Click-iT® EdU 904 
Imaging Kits (Life Technologies) according to the manufacturer. 905 
 906 
Microscopy. For RPA stains: Images of immunofluorescent staining were captured on the Zeiss 907 
510 Meta confocal microscope, using three lasers to give excitation at 647, 555 and 488 nM 908 
wavelengths. Images at each wavelength were collected sequentially at a resolution of 909 
approximately 1024 x 1024 pixels, using the Plan-Apochromat 100x/1.4 Oil objective.  All other 910 
immunofluorescent staining was imaged using the Leica DM6000B microscope using a HBO 911 
lamp with 100W mercury short arc UV bulb light source and four filter cubes, A4, L5, N3 and 912 
Y5  to produce excitations at wavelengths 360 488, 555 and 647 nm respectively. Images were 913 
captured at each wavelength sequentially using the Plan Apochromat HCX 100x/1.4 Oil 914 
objective at a resolution of 1392x1040 pixels. 915 
 916 
High-resolution fluorescence microscopy. Z-stack images were taken on an Olympus 917 
DeltaVision IX70 microscope. Using softWoRx imaging software, z-stacks were taken over 2μm 918 
at 0.1μm intervals at 100x magnification. The images were then deconvolved using softWoRx 919 
deconvolution software. Fluorescence intensity profiles were also generated using softWoRx 920 
to analyse 30 foci profiles per experiment.  921 
Statistics. Statistical analysis was by two-sided Students T-test throughout. *<p0.05, **p<0.01, 922 
***P<0.005. All center values are given as the mean and all error bars are standard error 923 
about the mean (s.e). 924 
 925 
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